In the present study, we demonstrated that PCa patients with high frequencies of HER-2/neu(780–788)-specific CD8+ T lymphocytes had better PFS compared with PCa patients with low frequencies, despite the fact that both patient groups had matched clinicopathological characteristics. The gene discussed is CD8A; the disease is posterior cortical atrophy.